Dalton Greiner Hartman Maher & Co Has Increased Huttig Bldg Prods Com (HBP) Holding By $1.04 Million, 8 Analysts Are Bullish BioCryst Pharmaceuticals, Inc. (BCRX) Last Week

June 29, 2017 - By Darrin Black

Dalton Greiner Hartman Maher & Co increased Huttig Bldg Prods Inc Com (HBP) stake by 70.22% reported in 2016Q4 SEC filing. Dalton Greiner Hartman Maher & Co acquired 173,700 shares as Huttig Bldg Prods Inc Com (HBP)’s stock rose 9.91%. The Dalton Greiner Hartman Maher & Co holds 421,074 shares with $2.78 million value, up from 247,374 last quarter. Huttig Bldg Prods Inc Com now has $179.60 million valuation. The stock increased 1.90% or $0.13 during the last trading session, reaching $6.96. About shares traded. Huttig Building Products Inc (NASDAQ:HBP) has risen 56.40% since June 29, 2016 and is uptrending. It has outperformed by 39.70% the S&P500.

Among 11 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. BioCryst Pharmaceuticals had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, January 6 by Jefferies. Bank of America downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, October 9 to “Neutral” rating. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Outperform” rating given on Tuesday, February 9 by FBR Capital. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Hold” rating by Jefferies on Friday, August 5. On Friday, May 26 the stock rating was maintained by Noble Financial with “Buy”. H.C. Wainwright maintained the shares of BCRX in report on Friday, May 26 with “Buy” rating. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by Rodman & Renshaw on Tuesday, February 9. The rating was upgraded by JMP Securities on Friday, December 16 to “Market Outperform”. As per Friday, August 7, the company rating was upgraded by Zacks. The firm has “Overweight” rating by Piperjaffray given on Friday, August 12. See BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) latest ratings:

26/05/2017 Broker: Noble Financial Rating: Buy Maintain
26/05/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0000 Maintain
16/02/2017 Broker: Ladenburg Thalmann Rating: Buy New Target: $11 Initiate

It closed at $5.82 lastly. It is down 75.08% since June 29, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company has market cap of $448.03 million. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. It currently has negative earnings. The Firm focuses on the treatment of rare diseases.

Since March 6, 2017, it had 0 buys, and 4 selling transactions for $139,783 activity. On Friday, March 10 STAAB THOMAS R II sold $29,445 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 3,250 shares.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.38, from 1 in 2016Q3. It improved, as 14 investors sold BioCryst Pharmaceuticals, Inc. shares while 23 reduced holdings. 19 funds opened positions while 32 raised stakes. 52.04 million shares or 2.90% more from 50.57 million shares in 2016Q3 were reported. Panagora Asset Mgmt Inc holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 31,477 shares. Retail Bank Of Montreal Can reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Blackrock Advsrs Ltd Co holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 38,500 shares. Federated Pa holds 0% or 83,835 shares in its portfolio. Legal And General Gru Public Ltd Co invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). D E Shaw And Company has 3.68 million shares. Venbio Select Advisor Limited Liability holds 2.09% or 1.63M shares. Moreover, Franklin Street Advsr Incorporated Nc has 0.05% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 49,000 shares. Arrowpoint Asset Mgmt Limited Liability invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Goldman Sachs Grp Inc invested in 0% or 741,440 shares. Gp One Trading L P has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Trexquant Inv L P stated it has 0.04% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Proshare Ltd Liability has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 60,527 shares. Hsbc Public Ltd Com invested in 0% or 12,654 shares. Wells Fargo Company Mn stated it has 118,433 shares.

Investors sentiment decreased to 1.53 in 2016 Q4. Its down 0.47, from 2 in 2016Q3. It worsened, as 8 investors sold HBP shares while 11 reduced holdings. 12 funds opened positions while 17 raised stakes. 9.83 million shares or 5.59% more from 9.31 million shares in 2016Q3 were reported. The New York-based Paradigm Cap Mngmt New York has invested 1.19% in Huttig Building Products Inc (NASDAQ:HBP). Art Llc reported 0.01% of its portfolio in Huttig Building Products Inc (NASDAQ:HBP). 83,179 were accumulated by Menta Cap Ltd Llc. Moreover, First Manhattan has 0% invested in Huttig Building Products Inc (NASDAQ:HBP) for 57,500 shares. Panagora Asset Mgmt Incorporated has 15,199 shares. Retail Bank Of America De, a North Carolina-based fund reported 19,600 shares. Ancora Advsrs Limited Liability holds 1,440 shares. Goldman Sachs Group Inc stated it has 16,390 shares or 0% of all its holdings. Blackrock Inv Ltd Liability invested in 0% or 3,936 shares. Tower Research Capital Llc (Trc) owns 628 shares for 0% of their portfolio. Wells Fargo Co Mn, California-based fund reported 9 shares. Weber Alan W owns 1.78 million shares or 7.13% of their US portfolio. Jacobs Levy Equity has 16,753 shares for 0% of their portfolio. 49,140 were reported by Axa. Eagle Global Advsr Limited Liability Corporation reported 0.02% in Huttig Building Products Inc (NASDAQ:HBP).

Dalton Greiner Hartman Maher & Co decreased Knight Transn Inc Com (NYSE:KNX) stake by 59,442 shares to 437,301 valued at $14.45 million in 2016Q4. It also reduced Cit Group Inc Com New (NYSE:CIT) stake by 10,852 shares and now owns 285,553 shares. Dicks Sporting Goods Inc Com (NYSE:DKS) was reduced too.